NO20051956D0 - Salmeterol superfin formulering - Google Patents

Salmeterol superfin formulering

Info

Publication number: NO20051956D0
Authority: NO; Norway
Prior art keywords: salmeterol; superfine formulation; superfine; formulation; salmeterol superfine
Prior art date: 2002-10-23

Application number

NO20051956A

Other languages

English (en)

Other versions

NO20051956L (no

Inventor

David Ganderton

Brian John Meakin

Gaetano Brambilla

David Andrew Lewis

Tanya Kathleen Church

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-23

Filing date

2005-04-21

Publication date

2005-04-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32087950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051956(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-21 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

2005-04-21 Publication of NO20051956D0 publication Critical patent/NO20051956D0/no

2005-07-22 Publication of NO20051956L publication Critical patent/NO20051956L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20051956A 2002-10-23 2005-04-21 Salmeterol superfin formulering NO20051956L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02023589A EP1415647A1 (en)	2002-10-23	2002-10-23	"Long-acting beta-2 agonists ultrafine formulations"
PCT/EP2003/006444 WO2004037227A1 (en)	2002-10-23	2003-06-18	Salmeterol superfine formulation

Publications (2)

Publication Number	Publication Date
NO20051956D0 true NO20051956D0 (no)	2005-04-21
NO20051956L NO20051956L (no)	2005-07-22

Family

ID=32087950

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051956A NO20051956L (no)	2002-10-23	2005-04-21	Salmeterol superfin formulering

Country Status (12)

Country	Link
US (1)	US8088362B2 (no)
EP (2)	EP1415647A1 (no)
AR (1)	AR040450A1 (no)
AT (1)	ATE421875T1 (no)
AU (1)	AU2003245965A1 (no)
BR (1)	BR0306663A (no)
CA (1)	CA2503183C (no)
DE (1)	DE60326053D1 (no)
ES (1)	ES2319887T3 (no)
NO (1)	NO20051956L (no)
PE (1)	PE20040314A1 (no)
WO (1)	WO2004037227A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
IT1303788B1 (it) *	1998-11-25	2001-02-23	Chiesi Farma Spa	Formulazioni di aerosol medicinali.
DZ2947A1 (fr) *	1998-11-25	2004-03-15	Chiesi Farma Spa	Inhalateur à compteur de dose sous pression.
US6315985B1 (en) *	1999-06-18	2001-11-13	3M Innovative Properties Company	C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) *	2000-01-07	2003-07-15	Chiesi Farma Spa	Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) *	2000-05-12	2003-08-27	Chiesi Farma Spa	Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) *	2000-05-22	2006-11-16	Chiesi Farmaceutici S.P.A.	Pharmaceutical solution formulations for pressurised metered dose inhalers
SI1273292T1 (en) *	2001-07-02	2004-12-31	Chiesi Farmaceutici S.P.A.	Optimised formulation of tobramycin for aerosolization
EP1415647A1 (en)	2002-10-23	2004-05-06	CHIESI FARMACEUTICI S.p.A.	"Long-acting beta-2 agonists ultrafine formulations"
EP1595531A1 (en)	2004-05-13	2005-11-16	CHIESI FARMACEUTICI S.p.A.	Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP2086617A4 (en) *	2006-10-26	2013-11-20	Next Breath Llc	INHALATION SYSTEM BASED ON PHOSPHOLIPIDS
US20100055045A1 (en) *	2008-02-26	2010-03-04	William Gerhart	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP3311820A1 (en) *	2008-02-26	2018-04-25	Sunovion Respiratory Development Inc.	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
CA2764867C (en) *	2009-06-09	2016-05-17	Elevation Pharmaceuticals, Inc.	Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
US20130274232A1 (en) *	2010-07-16	2013-10-17	Cipla Limited	Pharmaceutical Compositions
WO2021216779A1 (en) *	2020-04-21	2021-10-28	Amphastar Pharmaceuticals, Inc.	Anti-viral pharmaceutical formulations administered via devices for lung targeted delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9202519D0 (en) *	1992-02-06	1992-03-25	Glaxo Group Ltd	Medicaments
US6932962B1 (en) *	1994-12-22	2005-08-23	Astrazeneca Ab	Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
CA2217948C (en) *	1995-04-14	2002-02-19	Glaxo Wellcome Inc.	Metered dose inhaler for fluticasone propionate
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
US6423298B2 (en) *	1998-06-18	2002-07-23	Boehringer Ingelheim Pharmaceuticals, Inc.	Pharmaceutical formulations for aerosols with two or more active substances
CA2338753C (en) *	1998-07-24	2006-11-21	Jago Research Ag	Medicinal aerosol formulations
IT1303788B1 (it) *	1998-11-25	2001-02-23	Chiesi Farma Spa	Formulazioni di aerosol medicinali.
DZ2947A1 (fr) *	1998-11-25	2004-03-15	Chiesi Farma Spa	Inhalateur à compteur de dose sous pression.
US7074388B2 (en) *	1998-12-10	2006-07-11	Kos Life Science, Inc.	Water stabilized medicinal aerosol formulation
US20050048001A1 (en) *	1999-11-23	2005-03-03	Cripps Alan Leslie	Pharmaceutical formulations of salmeterol
ES2238334T3 (es) *	1999-12-24	2005-09-01	Glaxo Group Limited	Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
IT1317846B1 (it) *	2000-02-22	2003-07-15	Chiesi Farma Spa	Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009773D0 (en) *	2000-04-19	2000-06-07	Univ Cardiff	Particulate composition
IT1318514B1 (it) *	2000-05-12	2003-08-27	Chiesi Farma Spa	Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
WO2001089480A1 (en) *	2000-05-22	2001-11-29	Chiesi Farmaceutici S.P.A.	Stable pharmaceutical solution formulations for pressurised metered dose inhalers
SE0004750D0 (sv) *	2000-12-19	2000-12-19	Astrazeneca Ab	Novel formulation
US20020189610A1 (en) *	2001-02-01	2002-12-19	Karl-Heinz Bozung	Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US6455028B1 (en) *	2001-04-23	2002-09-24	Pharmascience	Ipratropium formulation for pulmonary inhalation
US20030018019A1 (en) *	2001-06-23	2003-01-23	Boehringer Ingelheim Pharma Kg	Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
EP1415647A1 (en)	2002-10-23	2004-05-06	CHIESI FARMACEUTICI S.p.A.	"Long-acting beta-2 agonists ultrafine formulations"
PT3536344T (pt) *	2002-03-01	2020-03-26	Chiesi Farm Spa	Formulação superfina de formoterol
EP1340492A1 (en) *	2002-03-01	2003-09-03	CHIESI FARMACEUTICI S.p.A.	Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1595531A1 (en) *	2004-05-13	2005-11-16	CHIESI FARMACEUTICI S.p.A.	Stable pharmaceutical solution formulations for pressurized metered dose inhalers

2002
- 2002-10-23 EP EP02023589A patent/EP1415647A1/en not_active Withdrawn
2003
- 2003-06-18 BR BR0306663-0A patent/BR0306663A/pt not_active Application Discontinuation
- 2003-06-18 WO PCT/EP2003/006444 patent/WO2004037227A1/en not_active Application Discontinuation
- 2003-06-18 DE DE60326053T patent/DE60326053D1/de not_active Expired - Lifetime
- 2003-06-18 US US10/531,867 patent/US8088362B2/en not_active Expired - Fee Related
- 2003-06-18 AT AT03738060T patent/ATE421875T1/de not_active IP Right Cessation
- 2003-06-18 AU AU2003245965A patent/AU2003245965A1/en not_active Abandoned
- 2003-06-18 ES ES03738060T patent/ES2319887T3/es not_active Expired - Lifetime
- 2003-06-18 CA CA2503183A patent/CA2503183C/en not_active Expired - Fee Related
- 2003-06-18 EP EP03738060A patent/EP1553922B1/en not_active Revoked
- 2003-06-20 PE PE2003000624A patent/PE20040314A1/es not_active Application Discontinuation
- 2003-06-20 AR AR20030102220A patent/AR040450A1/es not_active Application Discontinuation
2005
- 2005-04-21 NO NO20051956A patent/NO20051956L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ES2319887T3 (es)	2009-05-14
DE60326053D1 (de)	2009-03-19
NO20051956L (no)	2005-07-22
BR0306663A (pt)	2004-10-19
US8088362B2 (en)	2012-01-03
EP1553922A1 (en)	2005-07-20
AR040450A1 (es)	2005-04-06
ATE421875T1 (de)	2009-02-15
US20060120966A1 (en)	2006-06-08
CA2503183A1 (en)	2004-05-06
AU2003245965A1 (en)	2004-05-13
EP1553922B1 (en)	2009-01-28
WO2004037227A1 (en)	2004-05-06
PE20040314A1 (es)	2004-07-05
EP1415647A1 (en)	2004-05-06
CA2503183C (en)	2011-06-14

Publication	Publication Date	Title
DK3384931T3 (da)	2019-09-16	Superfin formoterolformulering
IS7806A (is)	2005-04-18	Ónæmisvaldandi samsetning
NO20052914D0 (no)	2005-06-15	Terapeutiske forbindelser
NO20050132D0 (no)	2005-01-11	Vaksinesammensetning
ATE368042T1 (de)	2007-08-15	Cephemverbindungen
DE10393374D2 (de)	2005-09-01	Zusammensetzung
IS7381A (is)	2004-08-03	Efnasambönd
IS7414A (is)	2004-08-19	Oxó-azabísýklísk efnasambönd
DK1596870T3 (da)	2007-10-15	Höjdosis-iblandronatformulering
NO20051956D0 (no)	2005-04-21	Salmeterol superfin formulering
DE60320902D1 (de)	2008-06-26	Zusammensetzungen mit ausgelöster Freisetzung
DE50310014D1 (de)	2008-07-31	Mähbalken
NO20045659L (no)	2004-12-27	Forbindelser
DK1492934T3 (da)	2010-10-04	Dørenhed
SE0500163L (sv)	2005-01-24	Sammansättning
DE60328488D1 (de)	2009-09-03	Ng
DK1569892T3 (da)	2012-08-27	Kalcilytiske forbindelser
NO20044140D0 (no)	2004-09-29	New Composition
NO20044164L (no)	2004-09-30	Farmasoytiske sammensetninger
DOP2002000508A (es)	2003-06-15	Composición farmaceutica
ITBO20020391A0 (it)	2002-06-18	Calcetto
SE0200449D0 (sv)	2002-02-13	Pharmaceutical formulation
SE0201660D0 (sv)	2002-05-31	Pharmaceutical formulation
SE0201667D0 (sv)	2002-06-03	New composition
SE0201759D0 (sv)	2002-06-10	New Composition

Legal Events

Date	Code	Title	Description
2015-01-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application